Hi-Tech Pharmacal to Release Fourth Quarter Earnings and Hold Conference Call on July 9, 2013

  Hi-Tech Pharmacal to Release Fourth Quarter Earnings and Hold Conference
  Call on July 9, 2013

Business Wire

AMITYVILLE, N.Y. -- July 3, 2013

Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced that the Company will
release results for its fourth quarter of Fiscal Year 2013 ended April 30,
2013, prior to the market opening on Tuesday July 9, 2013 and will hold a
conference call to discuss its financial results at 10 a.m. Eastern Time.

To access the conference call, dial toll free 877-280-4953, or 857-244-7310
for international callers, five minutes before the conference. The passcode of
the conference call is 15156675.

A replay of the conference call will be available after 12:00 p.m. on July 9,
2013, for one week by calling toll free 888-286-8010, or 617-801-6888 for
international callers. The passcode for the replay is 38645450. The call can
also be accessed on the Investor Relations page on the Company’s website
www.hitechpharm.com.

Hi-Tech is a specialty pharmaceutical company developing, manufacturing and
marketing generic and branded prescription and OTC products. The Company
specializes in difficult to manufacture liquid and semi-solid dosage forms and
produces a range of sterile ophthalmic, otic and inhalation products. The
Company’s Health Care Products Division is a leading developer and marketer of
branded OTC products for the diabetes marketplace. Hi-Tech’s ECR
Pharmaceuticals subsidiary markets branded prescription products.

This press release contains certain future projections and forward-looking
statements (statements which are not historical facts) with respect to the
anticipated future performance of Hi-Tech made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Such
future projections and forward-looking statements are not assurances, promises
or guarantees and investors are cautioned that all future projections and
forward-looking statements involve significant business, economic and
competitive risks and uncertainties, many of which are beyond Hi-Tech's
ability to control or estimate precisely, including, but not limited to, the
impact of competitive products and pricing, product demand and market
acceptance, new product development, the regulatory environment, including
without limitation, reliance on key strategic alliances, availability of raw
materials, fluctuations in operating results, loss of customers or employees,
the possibility that legal proceedings may be instituted against Hi-Tech and
other results and other risks detailed from time to time in Hi-Tech’s filings
with the Securities and Exchange Commission. The actual results will vary from
the projected results and such variations may be material. These statements
are based on management's current expectations and assumptions concerning the
future performance of Hi-Tech and are naturally subject to uncertainty and
changes in circumstances. No representations or warranties are made as to the
accuracy or completeness of any of the information contained herein,
including, but not limited to, any assumptions or projections contained herein
or forward-looking statements based thereon. We caution you not to place undue
reliance upon any such forward-looking statements which speak only as of the
date made, except to the extent specifically dated as of an earlier date.
Hi-Tech is under no obligation, and expressly disclaims any such obligation,
to update, alter or correct any inaccuracies herein, whether as a result of
new information, future events or otherwise.

Contact:

Hi-Tech Pharmacal Co., Inc.
Bill Peters, (631) 789-8228
CFO
 
Press spacebar to pause and continue. Press esc to stop.